Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01706991 · ClinicalTrials.gov registry record

Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner

A clinical trial of Amblyopia and Strabismus, sponsored by Rebiscan.

Completed
Registry status
32
Enrollment target
1
Study location

NCT01706991 is a study of Amblyopia and Strabismus that has completed, run by Rebiscan. The registered enrollment target is 32 participants, below the 164-participant average among 24 other Amblyopia trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01706991, a study of Amblyopia and Strabismus, has completed, sponsored by Rebiscan.

COMPLETED
Registry status
32 participants
Enrollment target
1
Study location

Study Summary

The purpose of this project is to compare the performance of the Pediatric Vision Scanner (PVS) with the Gold Standard Examination to determine the effectiveness of the PVS at detecting amblyopia and strabismus. All tests and observations will be done at a single visit over the course of approximately 30 minutes.

Conditions Studied

Interventions

  • DEVICE Pediatric Vision Scanner eye scan

Study Locations (1)

California

  • Doheny Eye Institute - Los Angeles

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2011-01
Est. Completion 2011-06

Sponsor

Rebiscan

9 total trials

What the Registry Record Tells You About NCT01706991

The ClinicalTrials.gov registry entry for NCT01706991 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 164-participant average among 24 other Amblyopia trials with a reported enrollment target (80% lower). The listed sponsor is Rebiscan, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Amblyopia appearing as the primary indexed condition, and to 1 intervention - of which Pediatric Vision Scanner eye scan is the first listed.

NCT01706991 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01706991 about?

NCT01706991 is a clinical study titled "Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner". The purpose of this project is to compare the performance of the Pediatric Vision Scanner (PVS) with the Gold Standard Examination to determine the effectiveness of the PVS at detecting amblyopia and strabismus. All tests and observations will be done at a single visit over the course of approximate...

What is the current status of trial NCT01706991?

This trial is currently completed. The enrollment target is 32 participants. The study started on 2011-01. Estimated completion is 2011-06.

What conditions does trial NCT01706991 study?

This clinical trial studies the following conditions: Amblyopia, Strabismus.

What interventions are being tested in trial NCT01706991?

The interventions under investigation include: Pediatric Vision Scanner eye scan (DEVICE).

Who is sponsoring clinical trial NCT01706991?

This trial is sponsored by Rebiscan, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01706991 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Amblyopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.